Evidence map›Paper›PMID 42799427›Full record

ArticleACS omega2026

UbC4 from Leishmania is a Druggable E2 Ubiquitin Conjugating Enzyme: Structural Basis and Fragment Hits for Future E2-Recruiting PROTAC Development.

Cécile Exertier, Lorenzo Antonelli, Anastasia Liuzzi, Marcus Ruffa, Vittorio Brufani, Gianni Colotti, Annarita Fiorillo, Andrea Ilari

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cécile ExertierInstitute of Molecular Biology and Pathology, Italian National Research Council (IBPM-CNR), c/o Department of Biochemical Sciences, Sapienza University of Rome, Ed. CU027, P.le A. Moro 5, 00185 Rome, Italy.ORCID https://orcid.org/0000-0001-7457-6895
Lorenzo AntonelliInstitute of Molecular Biology and Pathology, Italian National Research Council (IBPM-CNR), c/o Department of Biochemical Sciences, Sapienza University of Rome, Ed. CU027, P.le A. Moro 5, 00185 Rome, Italy.
Anastasia LiuzziInstitute of Molecular Biology and Pathology, Italian National Research Council (IBPM-CNR), c/o Department of Biochemical Sciences, Sapienza University of Rome, Ed. CU027, P.le A. Moro 5, 00185 Rome, Italy.
Marcus RuffaInstitute of Molecular Biology and Pathology, Italian National Research Council (IBPM-CNR), c/o Department of Biochemical Sciences, Sapienza University of Rome, Ed. CU027, P.le A. Moro 5, 00185 Rome, Italy.
Vittorio BrufaniInstitute of Molecular Biology and Pathology, Italian National Research Council (IBPM-CNR), c/o Department of Biochemical Sciences, Sapienza University of Rome, Ed. CU027, P.le A. Moro 5, 00185 Rome, Italy.
Gianni ColottiInstitute of Molecular Biology and Pathology, Italian National Research Council (IBPM-CNR), c/o Department of Biochemical Sciences, Sapienza University of Rome, Ed. CU027, P.le A. Moro 5, 00185 Rome, Italy.ORCID https://orcid.org/0000-0002-9913-0635
Annarita FiorilloInstitute of Molecular Biology and Pathology, Italian National Research Council (IBPM-CNR), c/o Department of Biochemical Sciences, Sapienza University of Rome, Ed. CU027, P.le A. Moro 5, 00185 Rome, Italy.
Andrea IlariInstitute of Molecular Biology and Pathology, Italian National Research Council (IBPM-CNR), c/o Department of Biochemical Sciences, Sapienza University of Rome, Ed. CU027, P.le A. Moro 5, 00185 Rome, Italy.ORCID https://orcid.org/0000-0002-7754-399X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis is a neglected disease that affects around two million people every year. Current treatments are often highly toxic or prone to resistance, underscoring the urgent need for new therapeutic strategies. PROTACs may offer a promising alternative, as they can potentially mitigate both toxicity and resistance. However, very little is known about the ubiquitin-proteasome system (UPS) in

Identifiers

PMID42799427
PMCPMC13613956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.